Adipose-Derived Stem Cells in Orthopedics: What the Clinical Evidence Shows in 2026

Orthopedic applications, particularly knee and hip osteoarthritis, represent the largest and most developed category of adipose-derived stem cell clinical research, with multiple systematic reviews, meta-analyses, and active Phase 2 and Phase 3 trials now in the published literature. Published data from randomized and observational trials have reported significant improvements in pain scores and functional outcomes in patients receiving ADSC-based interventions, though no ADSC-based orthopedic therapy has yet received FDA approval. This post summarizes the clinical evidence base as of 2026, maps the active trial pipeline, and explains what this evidence means for a patient considering banking or a physician evaluating whether to offer banking to orthopedic patients.

TLDR: ADSC-based orthopedic research is the most clinically advanced category in the adipose stem cell pipeline. Published systematic reviews and meta-analyses show pain and function improvements in knee osteoarthritis trials. Active Phase 2 and Phase 3 trials are recruiting. No ADSC orthopedic therapy is FDA-approved. Banking preserves autologous cells for potential access to these pathways as they mature. Orthopedic and sports medicine physicians are among the best-positioned providers for banking.

Important Disclaimer: Save My Fat does not provide FDA-approved treatments or cures for any disease, including joint disease or osteoarthritis. No ADSC-based orthopedic therapy has received FDA approval as of the date of this post. Banking adipose tissue does not guarantee eligibility, access, or clinical benefit from any future therapy, clinical trial, or medical program. The clinical evidence described in this post is from published research and active trials, describing what is being investigated rather than what is proven or approved. All content is for educational purposes only and does not constitute medical advice. Consult your physician before making any healthcare decision.

Osteoarthritis is the most prevalent joint disease in the world, affecting hundreds of millions of people globally, and the treatment options for moderate-to-severe disease are essentially unchanged across decades of clinical practice: NSAIDs, corticosteroid injections, hyaluronic acid supplementation, and eventual joint replacement. For patients and physicians who have watched this treatment landscape stagnate while the underlying biological research has accelerated, the ADSC orthopedic pipeline represents one of the most compelling near-term clinical developments in the field.

The evidence is not speculative. Multiple peer-reviewed systematic reviews and meta-analyses of published clinical trials have now reported consistent improvements in pain and functional outcomes across different ADSC preparation methods, different administration techniques, and different trial designs. The signal is reproducible and growing in scale. The question for 2026 is not whether ADSCs have biological activity in joint disease, because the evidence base has begun to answer that. The question is which specific preparation, dose, and administration protocol will produce the definitive Phase 3 data needed for FDA approval, and how long that will take.

This post covers the evidence in four sections: the biological mechanism, the published clinical data, the active trial pipeline, and the specific implications for patients and physicians considering banking in the context of joint health.

Why Joint Disease Is the Leading ADSC Application

The Disease Burden

Osteoarthritis affects hundreds of millions of people globally and is the leading cause of pain-related disability in adults over fifty. Knee osteoarthritis alone affects approximately fourteen million people in the United States, and the prevalence scales sharply with age across most populations. Conventional pharmacological options provide symptom relief but do not address the underlying cartilage degradation and joint inflammation that drive disease progression, and the published clinical evidence base on standard-of-care interventions has been clear about that limitation for years.

Why ADSCs Are Biologically Suited for Joint Disease

The three core mesenchymal stem cell properties map directly onto the pathophysiology of osteoarthritis. Differentiation is the first: ADSCs can differentiate into chondrocyte-like cells under the right conditions, providing a potential source for cartilage repair at the site of injury. Immunomodulation is the second: osteoarthritis involves chronic low-grade synovial inflammation, and mesenchymal stem cell anti-inflammatory signaling targets this mechanism directly rather than masking its effects. Paracrine signaling is the third: mesenchymal stem cell-secreted growth factors, including TGF-beta, IGF-1, and BMP-2, support chondrocyte survival, extracellular matrix production, and broader tissue repair signaling in the joint environment.

The 2019 MSC biology review from Pittenger and colleagues in npj Regenerative Medicine summarizes these mechanisms in physician-appropriate depth, and the foundational 2002 Zuk et al. paper in Molecular Biology of the Cell established why adipose tissue is the preferred source for accessing these mesenchymal stem cell populations. Save My Fat’s comparison of mesenchymal stem cells across sources puts the adipose source in context against the alternatives. This biological fit is why orthopedics has the most developed ADSC evidence base of any clinical category, and why trial activity in joint disease consistently outpaces trial activity in other indication areas.

The Published Clinical Evidence

Systematic Reviews and Meta-Analyses

The most rigorous available summary of the ADSC orthopedic evidence base comes from published systematic reviews and meta-analyses, which aggregate data across multiple trials to assess overall effect size and consistency of findings. This is the evidence level that matters most in evaluating the field, because individual trials can produce results that do not replicate while consistent meta-analytic findings signal a reproducible effect.

A published 2021 systematic review of ADSC-based treatments for knee osteoarthritis analyzed data from multiple randomized and observational trials and reported statistically significant improvements in pain scores and functional outcome scores at follow-up points ranging from six to twenty-four months. The effect sizes reported were clinically meaningful rather than only statistically significant, which is the important distinction for clinical interpretation.

A 2022 meta-analysis specifically examining ADSC injections for knee osteoarthritis pooled data from multiple trials and confirmed reductions in pain scores and improvements in knee function, with favorable safety profiles across the included studies. The consistency between this meta-analysis and the 2021 systematic review strengthens the overall signal, because independent teams using different inclusion criteria and analytic methods have reached similar conclusions.

Key Individual Trials

Beyond the meta-analytic evidence, several individual trials have contributed important data to the field. The registered Lipogems MFAT knee OA trial evaluated micro-fragmented adipose tissue for knee osteoarthritis in a multi-center study, and published results from that trial and related investigations described in the Cattaneo 2018 clinical paper have reported sustained improvements in pain and function at twelve-month follow-up.

A 2020 systematic review of MFAT-specific trials for orthopedic applications confirmed pain and function improvements across multiple study designs and application sites including knee, hip, and shoulder. The breadth of the MFAT evidence base across joint types is one of the reasons the preparation method has attracted substantial clinical research interest. A 2021 study extended the evidence to non-knee orthopedic applications including rotator cuff pathology, plantar fasciitis, and hip osteoarthritis, with similarly favorable early-phase results across each indication.

What the Evidence Does Not Yet Establish

Honest clinical context matters as much as the positive findings, and this section is substantive rather than a token disclaimer. No ADSC orthopedic therapy has completed a large Phase 3 randomized controlled trial and received FDA approval for a specific orthopedic indication. Long-term follow-up data beyond twenty-four months is limited in most of the published studies. The optimal cell preparation method, whether isolated cell injection, micro-fragmented tissue, or expanded cell preparations, has not been definitively established through direct head-to-head comparative trials. Optimal dose and injection protocol remain areas of active investigation rather than settled parameters. Placebo-controlled trial data is limited in the published evidence base, and the absence of blinded controls in some studies is a methodological limitation that careful reviewers consistently flag, as the 2022 meta-analysis discussion acknowledges.

This context is important for both patients and physicians. The evidence is strong enough to justify an active clinical research program across the orthopedic indications and to support banking as a preservation strategy for patients who want to position themselves for future access. The evidence is not yet strong enough to claim that ADSC injection is a proven standard of care, and any provider representing it as such is making a claim the published literature does not support.

The Active Clinical Trial Pipeline

Current Scale

Active clinical trials involving adipose-derived stem cells for orthopedic applications are recruiting now. The pipeline spans Phase 1, Phase 2, and Phase 3 levels across knee osteoarthritis, hip osteoarthritis, rotator cuff injury, cartilage defects, and tendon pathology, and both the orthopedic-specific ADSC trial search and the adipose mesenchymal osteoarthritis trial search on ClinicalTrials.gov are worth reviewing for patients or physicians who want to evaluate the current landscape directly.

What Phase 2 and Phase 3 Activity Means

Phase 2 trials establish efficacy signals and dose-response relationships in patient populations that match the intended treatment population. Phase 3 trials are the pivotal studies that generate the evidence base required for FDA approval, and they are typically larger, more rigorously controlled, and more expensive than earlier phases. Active Phase 2 and Phase 3 ADSC orthopedic trials mean the field has moved past early-stage feasibility questions and is now working toward the evidence threshold for regulatory approval. Save My Fat’s explainer on what ClinicalTrials.gov phases mean covers the phase structure in patient-appropriate depth for readers who want context on what they see in the trial registry.

The Approval Precedent

The December 2024 FDA approval of the first mesenchymal stem cell product, documented in the FDA’s approved cellular and gene therapy products database, established that the FDA will approve MSC-based therapies when Phase 3 evidence supports them. The approved product is not an ADSC orthopedic therapy. It is an allogeneic bone-marrow-derived MSC therapy for a specific pediatric immune condition. What it establishes for the ADSC orthopedic pipeline is that the regulatory pathway is demonstrably navigable for this cell class. For patients banking today, the orthopedic application category is the one most likely to produce an FDA-approved therapy within the second half of this decade, though no specific approval timeline can be promised.

What This Means for Patients Considering Banking

The Joint Health Banking Case

For a patient who has or is at risk for joint disease, which includes most adults over forty, the ADSC orthopedic evidence base makes a specific argument for banking now. The biological mechanism is validated across multiple trials and multiple preparation methods. The clinical evidence base is consistent and growing, with meta-analytic findings reinforcing individual trial results. Active Phase 2 and Phase 3 trials are moving toward the evidence threshold for approval. Banking earlier preserves cells at higher biological quality, before the biological stress of joint disease, systemic inflammation, and age-related cell quality decline affects the autologous starting material, as the published MSC biology literature documents. Save My Fat’s complete guide to banking walks through the banking value proposition in patient-facing depth, and the patient-facing introduction to adipose-derived stem cells provides the underlying biological background.

Clinical Trial Enrollment as an Alternative Pathway

Patients who want access to ADSC orthopedic therapies now, rather than waiting for approval, should also evaluate clinical trial enrollment. Active recruiting trials for knee and hip osteoarthritis can be found through the adipose mesenchymal osteoarthritis trial search on ClinicalTrials.gov. Trial participation typically provides access to investigational therapy at no cost to the patient, under the most rigorous safety monitoring available in the field, and Save My Fat’s resource on finding legitimate clinical trials covers the evaluation framework patients should use when reviewing specific trial listings.

Banking and trial enrollment are complementary rather than mutually exclusive. A patient who has banked may be better positioned for autologous-cell trials that require preserved starting material. A patient who enrolls in a trial now has access to the current best investigational evidence. Patients who want both pathways open should discuss the order of operations with their physician, and Save My Fat’s expanded access overview covers the third relevant pathway for patients with qualifying serious conditions.

What This Means for Orthopedic and Sports Medicine Physicians

Patient Population Overlap

The patients most likely to be interested in banking are the same patients an orthopedic or sports medicine physician already sees. Active adults with early-to-moderate joint disease who want to preserve function, delay joint replacement, and remain engaged with emerging treatment options are the core demographic for both the existing practice and the banking service. This is service line extension rather than patient acquisition, and the implication is that the marginal cost of introducing banking to an existing orthopedic practice is materially lower than introducing any service that requires building a new patient base from scratch.

The Referring and Treating Physician Model

Save My Fat partner providers who perform banking become the referring and treating physician for any future vial access, whether the pathway is a clinical trial, expanded access, or an FDA-approved therapy. An orthopedic physician who banks patients today is the physician those patients will return to when ADSC orthopedic therapies reach approval. That is a long-term practice relationship built on a single procedure, and it is a different practice-building dynamic than the episodic patient relationship that characterizes most orthopedic visits. Save My Fat’s overview of how banking works describes the referring-physician-treating-physician continuity that underpins this dynamic.

The Conversation Is Already Happening

Orthopedic patients are already asking about stem cells for their joints. The physician who can engage that question accurately, pointing to the evidence base, explaining the difference between compliant banking and unapproved clinic injections, and offering a preservation option for patients who are not candidates for active trials, is building trust with a health-forward patient population that will remember the conversation. The physician who deflects the question loses that credibility moment, and often loses the patient to a less compliant provider. Save My Fat’s overviews of ADSC autoimmune and inflammatory research and FDA regulations for adipose tissue give partner providers additional reference material for conversations that span beyond the orthopedic indication area.

Evidence Summary Table

The 2022 knee osteoarthritis meta-analysis, the 2020 MFAT systematic review, the 2021 non-knee orthopedic applications study, and the Lipogems trial registration together form the primary reference set for the evidence levels summarized in the table. Patients and physicians interested in evaluating individual studies should review the primary sources rather than relying on summary statements alone.

Frequently Asked Questions

Is there an FDA-approved ADSC treatment for osteoarthritis?

No. As of 2026, no ADSC-based therapy for osteoarthritis has received FDA approval. The evidence base supports active clinical development, and active Phase 2 and Phase 3 trials are recruiting. The December 2024 FDA approval of the first MSC product for a pediatric immune condition established the regulatory pathway that orthopedic ADSC therapies are working toward, but approval for a specific orthopedic indication requires the Phase 3 evidence for that indication to be generated first.

What is the difference between banking for joint disease and getting MFAT injections now?

MFAT is a same-day procedure using freshly processed tissue, positioned as an investigational intervention for a current joint condition. Banking preserves cells in cryostorage for potential future use in FDA-regulated pathways, including approved therapies and clinical trials as they become available. They serve different timelines and different patient goals, and Save My Fat’s complete guide to banking covers the distinction in more depth. Neither is a treatment in the FDA-approved sense, and patients considering either should discuss both with their physician.

Are there active clinical trials I can enroll in now for knee arthritis?

Yes. Active recruiting trials for ADSC-based approaches to knee and hip osteoarthritis are listed through the adipose mesenchymal osteoarthritis trial search on ClinicalTrials.gov. Trial enrollment typically provides access to investigational therapy under rigorous monitoring at no cost to the patient, though inclusion and exclusion criteria are trial-specific. Save My Fat’s guide on finding legitimate clinical trials covers the evaluation framework patients should use before enrolling.

Should I bank before or after getting a cortisone injection?

Discuss with your physician. Corticosteroid injections create a local anti-inflammatory environment at the injection site, and the harvest for banking is from subcutaneous fat at the abdomen or flank rather than from the joint itself, so the direct impact on cell quality may be limited. Timing considerations depend on the specific patient’s treatment history, the interval between procedures, and the clinical judgment of the treating physician. There is no universal rule that applies across all patients.

Which type of ADSC preparation shows the most evidence for joint disease?

The evidence base spans multiple preparation methods: isolated ADSC injection, micro-fragmented adipose tissue preparations, and culture-expanded cell preparations. The most consistent evidence in terms of volume and replication is for micro-fragmented tissue in knee osteoarthritis, driven by the Lipogems trials and the published systematic reviews. Isolated ADSC injection also has a strong evidence base from the meta-analytic literature. Enzymatically processed stromal vascular fraction preparations are a distinct regulatory category with their own evidence considerations, and the FDA has applied scrutiny to enzymatically processed cell preparations under the minimal manipulation standard of 21 CFR Part 1271. Definitive comparative data between preparation methods from direct head-to-head trials is not yet available.

Key Takeaways

Orthopedic applications, especially knee osteoarthritis, represent the most clinically advanced category in the adipose-derived stem cell pipeline. The peer-reviewed evidence base is larger and more consistent than in any other indication area, and the trial activity is concentrated at the later phases that matter most for regulatory approval.

Published systematic reviews and meta-analyses have reported pain and functional improvements across multiple trial designs and multiple ADSC preparation methods. The signal is reproducible across independent research teams and across different preparation approaches, which strengthens the overall interpretation of the findings. The safety profiles across the included studies have been favorable.

No ADSC orthopedic therapy has received FDA approval. Active Phase 2 and Phase 3 trials are building the evidence base toward that threshold. The December 2024 Ryoncil approval established that the FDA will approve MSC-based therapies when Phase 3 evidence supports them, which is the regulatory precedent the orthopedic pipeline is working within.

Banking earlier preserves cells at higher biological quality. The effects of joint disease progression, systemic inflammation, and age-related cell decline on the autologous starting material make the case for banking at the earliest point of relative health, rather than waiting until a qualifying condition develops.

Orthopedic, sports medicine, and pain management physicians are among the best-positioned providers for banking. Their patient populations are exactly the demographic most likely to bank and most likely to benefit from future ADSC orthopedic therapies. The service line extension involves no new equipment and no new patient acquisition, and it builds a long-term practice relationship rather than an episodic one.

Banking and clinical trial enrollment are complementary rather than mutually exclusive. Patients who want both pathways open should discuss sequencing with their physician, and patients with qualifying conditions who cannot access an appropriate trial may find the expanded access pathway relevant as a separate consideration.

Ready to Offer Banking to Your Orthopedic Patients?

Before contacting Save My Fat: adipose tissue banking is a preservation service for potential future use in FDA-regulated pathways, not a treatment or a guarantee of access to any specific clinical trial, therapy, or product. No ADSC-based orthopedic therapy is FDA-approved for osteoarthritis or any other joint disease indication, and banking cannot be represented to patients as a treatment for joint disease. Physicians considering partnership should independently verify applicable state licensing and informed-consent requirements, particularly in Florida, Utah, and Nevada, which have stem cell-specific statutes.

Your patients are already asking about stem cells for their joints. The evidence base supports that question as a legitimate one. Banking gives them a compliant, physician-led option for preserving their cells ahead of the therapies this evidence base is building toward, and it gives you a service line that fits an existing orthopedic or sports medicine practice without new equipment or new patient acquisition.

Save My Fat partner providers are the local clinical resource for patients in their area who want to bank. The provider who banks an orthopedic patient today is the provider that patient returns to when ADSC therapies reach approval.

To review the full program structure, visit the provider program overview. To begin onboarding as a partner, visit the partner sign-up page.

Save My Fat provides adipose tissue banking services in partnership with a U.S.-based tissue bank for laboratory operations. Save My Fat does not provide medical treatments, clinical trial enrollment, or Expanded Access services.

This article is for educational purposes only and does not constitute medical or legal advice. Legal and medical review including neurology and neurosurgery input is required before publication. Please consult your neurologist or neurosurgeon before making any decisions about neurologic treatment or research participation.

About the author: Oscar Tellez is the founder and CEO of Save My Fat. He holds a Bachelor of Science in Exercise Science and Health Promotion from Florida Atlantic University. He has spent more than a decade in the regenerative medicine industry across product distribution, laboratory and vendor relationships, and provider training. He is not a licensed clinician, and this article is educational, not medical advice.

Related guide: adipose stem cell trials.